Published in Gastroenterology on February 01, 1994
Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol (2012) 1.46
The Effect of an Aqueous Extract of Teucrium polium on Glutathione Homeostasis In Vitro: A Possible Mechanism of Its Hepatoprotectant Action. Adv Pharmacol Sci (2010) 0.95
Hepatitis after the use of germander, a herbal remedy. CMAJ (1996) 0.81
Reactive metabolites in the biotransformation of molecules containing a furan ring. Chem Res Toxicol (2012) 0.78
Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs. Medicines (Basel) (2016) 0.75
Organ-specific disease provoked by systemic autoimmunity. Cell (1996) 6.44
From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity (1999) 5.38
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med (1997) 3.49
Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med (2001) 2.95
Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology (1999) 2.63
Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology (1995) 2.54
Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology (1991) 2.38
Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol (1999) 2.33
Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology (2000) 2.21
Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon. Lancet (1991) 2.14
Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med (2000) 2.08
Genetic influences on the end-stage effector phase of arthritis. J Exp Med (2001) 1.99
An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology (1999) 1.92
The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology (2001) 1.87
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut (2000) 1.84
Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther (1995) 1.78
A new intermediate in naphthoquinone and menaquinone biosynthesis. Biochem Biophys Res Commun (1970) 1.75
Epithelioid hemangioendothelioma, multiple focal nodular hyperplasias, and cavernous hemangiomas of the liver. Arch Pathol Lab Med (1999) 1.71
Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology (1998) 1.69
Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut (2002) 1.68
Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses. Gut (2000) 1.63
Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology (1985) 1.62
Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology (1998) 1.61
Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology (1997) 1.61
Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology (1986) 1.59
Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology (1998) 1.58
PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res (1995) 1.54
Expression of complement-regulatory proteins in normal and UW-preserved human liver. Gastroenterology (1994) 1.54
Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology (2001) 1.51
Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol (2001) 1.51
Randomized controlled trial of adenine arabinoside 5'-monophosphate in chronic active hepatitis B: comparison of the efficacy in heterosexual and homosexual patients. Hepatology (1989) 1.50
Peliosis hepatis in recipients of renal transplants. Gut (1978) 1.48
Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol (1996) 1.46
Chronic hepatitis in kidney allograft recipients. Lancet (1990) 1.45
Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C. Ann Intern Med (1997) 1.44
Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol (2001) 1.44
Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology (1982) 1.43
The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab (2004) 1.43
Liver in obesity. Gut (1985) 1.39
Exacerbation of multiple sclerosis after the administration of recombinant human interferon alfa. JAMA (1989) 1.38
Nodular regenerative hyperplasia of the liver. Report of six cases and review of the literature. Gastroenterology (1978) 1.29
A new hepadnavirus endemic in arctic ground squirrels in Alaska. J Virol (1996) 1.26
Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology (1996) 1.26
Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochem Pharmacol (1990) 1.25
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer (2005) 1.24
Auxiliary liver transplantation: regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure--a multicenter European study. Hepatology (1996) 1.23
Effects of inducers and epoxide hydrase on the metabolism of benzo(a)pyrene by liver microsomes and a reconstituted system: analysis by high pressure liquid chromatography. Proc Natl Acad Sci U S A (1974) 1.21
Acute ethanol administration oxidatively damages and depletes mitochondrial dna in mouse liver, brain, heart, and skeletal muscles: protective effects of antioxidants. J Pharmacol Exp Ther (2001) 1.19
Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol (1997) 1.18
Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene (1999) 1.18
Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol (1987) 1.17
Portal hypertension in systemic mastocytosis. Gastroenterology (1978) 1.17
Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology (1990) 1.16
Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholic patients. J Hepatol (1997) 1.16
Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf (1996) 1.16
Idiopathic portal hypertension (perisinusoidal fibrosis) after renal transplantation. Gut (1979) 1.15
[Hepatitis caused by diclofenac]. Gastroenterol Clin Biol (1983) 1.15
Acute and chronic drug-induced hepatitis. Baillieres Clin Gastroenterol (1988) 1.15
Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology (1988) 1.15
Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology (2001) 1.14
Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice. Hepatology (2000) 1.13
Successful endoscopic obturation of gastric varices with butyl cyanoacrylate. Hepatology (1989) 1.13
Perhexiline maleate-induced cirrhosis. Gastroenterology (1979) 1.12
The intraportal lymphoid nodule and its environment in chronic active hepatitis C: an immunohistochemical study. Hepatology (1993) 1.12
Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology (1993) 1.11
Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut (2003) 1.11
Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol (1983) 1.11
Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther (1990) 1.10
Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology (1978) 1.10
Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis. A clinical and immunological study of a series of 150 patients with primary biliary cirrhosis. Gastroenterology (1990) 1.10
Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol (1997) 1.10
The ciliated hepatic foregut cyst, an unusual bronchiolar foregut malformation: a histological, histochemical, and immunohistochemical study of 7 cases. Hum Pathol (2000) 1.09
Epithelioid hemangioendothelioma of the liver. Diagnostic features and role of liver transplantation. Gastroenterology (1988) 1.07
Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat (2006) 1.07
Amodiaquine-induced fulminant hepatitis. J Hepatol (1988) 1.05
Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases. Am J Gastroenterol (2001) 1.05
Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology (2005) 1.05
Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology (2001) 1.05
Mechanism for the hepatotoxicity of the antiandrogen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. J Pharmacol Exp Ther (1992) 1.04
Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest (1990) 1.04
Right-sided endocarditis complicating peritoneovenous shunting for ascites. Arch Intern Med (1983) 1.02
Liver-specific expression and high oncogenic efficiency of a c-myc transgene activated by woodchuck hepatitis virus insertion. Oncogene (1994) 1.02
A facile synthesis of arene oxides at the K regions of polycylic hydrocarbons. J Am Chem Soc (1974) 1.01